2026 Volume: 02 Issue: 08 www.ijrpa.com ISSN 2456-9995 Research Article

International Journal Research Publication Analysis

Page: 01-13

ARTFICIAL INTELLIGENCE IN PHARMACEUTICAL TECHNOLOGY AND DRUG DELIVERY DESIGN INNOVATIONS, APPLICATIONS, AND FUTURE DIRECTIONS IN AI-DRIVEN PHARMA.

[1]*V. Archana, [2]Gattu Jyothi, [3]Dr. M. Sudhakar

[1]M. Pharmacy, [2]Assistant Professor,

[3]Department of Pharmaceutics, Malla Reddy College of Pharmacy, Hyderabad, India.

Article Received: 11 July 2026
Article Revised: 31 July 2026
Published on: 20 August 2026

***Corresponding Author: V. Archana**
M. Pharmacy, Malla Reddy College of Pharmacy, Hyderabad, India.

DOI: https://doi-doi.org/101555/ijrpa.4726

ABSTRACT

Artificial Intelligence (AI) has emerged as a transformative technology in the pharmaceutical industry, significantly improving drug discovery, pharmaceutical technology, and drug delivery system design. Traditional drug development processes are time-consuming, costly, and complex, often requiring many years of research and large financial investments. AI techniques, including machine learning (ML) and deep learning (DL), enable the analysis of large biomedical datasets to identify potential drug targets, predict molecular interactions, and optimize drug candidates with greater speed and accuracy. These technologies also support virtual screening, structure–activity relationship modelling, toxicity prediction, and drug repurposing, thereby accelerating the early stages of drug development. In pharmaceutical technology, AI assists in the development and optimization of oral solid dosage forms and other drug delivery systems by predicting formulation behaviour, dissolution patterns, and stability. AI-based computational models also contribute to pharmacokinetic (PK) and pharmacodynamic (PD) studies by predicting drug absorption, distribution, metabolism, and excretion (ADME) properties. Furthermore, AI improves healthcare services through applications such as automated pharmacy systems, predictive inventory management, and robotic medication preparation.

Despite these advantages, challenges such as data limitations, algorithm bias, lack of transparency, regulatory concerns, and ethical considerations remain significant. This review article discusses the major applications of AI in pharmaceutical technology, drug discovery, pharmacokinetics, and drug delivery design, while also highlighting its advantages, limitations,

and future prospects in modern pharmaceutical research.

INDEX TERMS: Artificial Intelligence (AI), Machine Learning (ML), Drug Discovery, Drug Delivery Systems, Pharmaceutical Technology, Pharmacokinetics (PK), Pharmacodynamics (PD), Oral Solid Dosage Forms, Virtual Screening, Drug Design, Deep Learning, Pharmaceutical Manufacturing.

1. INTRODUCTION

The rapid advancement of Artificial Intelligence (AI) is transforming many areas of healthcare and biomedical research. In the pharmaceutical industry, AI has emerged as a powerful tool for improving drug discovery, pharmaceutical manufacturing, and drug delivery system design. By analyzing large and complex datasets, AI can identify patterns, make predictions, and support decision-making processes that were previously time- consuming and difficult using traditional methods.[1]

Fig1. Conceptual illustration of Artificial Intelligence–assisted drug discovery and pharmaceutical development, integrating biomedical data, molecular analysis, and predictive modelling to accelerate the identification and optimization of therapeutic compounds.

These capabilities are helping researchers accelerate the development of safer and more effective medicines. The pharmaceutical industry plays a vital role in improving global health and saving lives.

Continuous innovation in drug development, manufacturing, packaging, and marketing is necessary to address healthcare challenges and respond to emergencies such as the COVID-19 pandemic. New drugs, including small molecules and biologics, are developed to be more effective and stable, but they must be carefully tested for toxicity before approval.

The industry also faces challenges such as skill shortages, supply chain disruptions, and manufacturing issues. During the COVID-19 pandemic, many pharmaceutical operations, including clinical trials and vaccine distribution, were affected. Problems like cold chain failures, natural disasters, cyberattacks, and transport delays can cause major financial losses and reduce customer trust.[2]

Artificial Intelligence (AI) and Machine Learning (ML) can help overcome these challenges. They improve supply chain management, support research and development, and enhance decision-making. AI can also make clinical trials more efficient by using wearable devices and sensors to collect real-time patient data remotely, reducing the need for frequent hospital visits.AI and ML are widely used in drug discovery, including identifying drug targets, predicting protein structures, designing new molecules, and analyzing clinical trial data. With increasing data from wearable devices and medical instruments, deep learning algorithms help process and analyze information more efficiently.

Overall, AI technologies are transforming pharmaceutical research and manufacturing, improving drug development processes and supporting the growth of personalized medicine in the future.[3]

2. AI FOR DRUG DISCOVERY

AI has revolutionized drug research and discovery in numerous ways. Some of the key contributions of AI in this domain include the following:

2.1 Target Identification

Systems can analyze diverse data types, such as genetic, proteomic, and clinical data, to identify potential therapeutic targets. By uncovering disease-associated targets and molecular pathways, AI assists in the design of medications that can modulate biological processes.

2.2 Virtual Screening

AI enables the efficient screening of vast chemical libraries to identify drug candidates that have a high likelihood of binding to a specific target. By simulating chemical interactions and predicting binding affinities, AI helps researchers prioritize and select compounds for experimental testing, saving time and resources.

2.3 Structure-Activity Relationship (SAR) Modelling

AI models can establish links between the chemical structure of compounds and their biological activity. This allows researchers to optimize drug candidates by designing molecules with

desirable features, such as high potency, selectivity, and favorable pharmacokinetic profiles.[4]

2.4. De Novo Drug Design

Using reinforcement learning and generative models, AI algorithms can propose novel drug- like chemical structures. By learning from chemical libraries and experimental data, AI expands the chemical space and aids in the development of innovative drug candidates.

2.5. Optimization of Drug Candidates

AI algorithms can analyze and optimize drug candidates by considering various factors, including efficacy, safety, and pharmacokinetics. This helps researchers fine-tune therapeutic molecules to enhance their effectiveness while minimizing potential side effects.

2.6. Drug Repurposing

AI techniques can analyze large-scale biomedical data to identify existing drugs that may have therapeutic potential for different diseases. By repurposing approved drugs for new indications, AI accelerates the drug discovery process and reduces costs.

2.7. Toxicity Prediction

AI systems can predict drug toxicity by analyzing the chemical structure and characteristics of compounds. Machine learning algorithms trained on toxicology databases can anticipate harmful effects or identify hazardous structural properties. This helps researchers prioritize safer chemicals and mitigate potential adverse responses in clinical trials.[5]

3. AI FOR DEVELOPMENT OF DIFFERENT DOSAGE FORM

3.1 AI in Oral Solid Dosage Forms (Tablets and Capsules)

Formulation Optimization – Selection of excipients and composition. Dissolution Prediction – Predicting drug release profiles.

Process Optimization – Compression force, granulation, coating parameters. Stability Prediction – Shelf-life and degradation analysis.

3.2 AI in Liquid Dosage Forms

Solubility Prediction – Improving drug solubility in solutions and suspensions Stability Analysis — Predicting precipitation and degradation

Excipient Selection – Optimizing solvents, preservatives, and stabilizers

3.3 AI in Semi-Solid Dosage Forms

Formulation Design – Optimization of creams, gels, and ointments Viscosity and Rheology Prediction – Controlling texture and spreadability Drug Release Modeling – Predicting drug diffusion through skin.

3.4 AI in Controlled and Sustained Release Systems

Release Kinetics Prediction – Modeling controlled drug release patterns Polymer Selection – Identifying suitable polymers for sustained delivery Formulation Optimization – Adjusting matrix and coating parameters

3.5 AI in Nanotechnology-Based Drug Delivery

Nanoparticle Design – Optimization of particle size and surface
properties Targeted Drug Delivery – Predicting targeting efficiency Drug Loading Efficiency – Improving drug encapsulation and stability

3.6 AI in Transdermal Drug Delivery Systems

Skin Permeation Prediction – Modeling drug penetration through skin
Patch Design Optimization – Improving adhesive and drug release properties

3.7 AI in Inhalation Drug Delivery

Particle Size Prediction – Optimizing aerosol particle size Deposition Modeling – Predicting drug deposition in lungs.[7]

4. LIMITATIONS OF AI TOOLS

Despite their benefits, AI-based models have some limitations, such as the need for large datasets, potential biases, and lack of interpretability. Therefore, AI-based models should be used in combination with traditional experimental methods to ensure the safety and efficacy of drugs. Some of the limitations are highlighted below:

4.1 Lack of Transparency

AI models often function as “black boxes,” meaning their internal decision-making process is difficult to interpret. This lack of transparency makes it challenging for researchers and regulatory agencies to verify how predictions are generated. As a result, gaining regulatory approval and building trust among clinicians and scientists becomes difficult.

4.2 Limited Availability of Data

AI models require large and high-quality datasets for accurate predictions. However, in many cases, especially with rare diseases or new drugs, sufficient data may not be available. Limited or non-representative datasets can lead to inaccurate or biased predictions, reducing the reliability of AI models in drug development.

4.3 Biases in Data

The accuracy of AI models depends heavily on the quality of the training data. If the dataset contains biases or lacks representation from diverse patient populations, the model may produce biased outcomes. For example, underrepresentation of certain demographics in clinical trials

can affect the model's ability to predict drug responses for those groups.

4.4 Inability to Incorporate New Data

After training, updating AI models with new clinical or experimental data can be difficult and time-consuming. Since drug development constantly produces new information, models must be retrained regularly. Failure to update models may lead to outdated predictions and poor decision-making.[8]

4.5 Limited Ability to Account for Variability

AI models are often trained to recognize average trends in large datasets. However, drug responses may vary significantly among individuals due to genetic, environmental, or physiological differences. This limitation may reduce the accuracy of predictions for patients who deviate from average responses.

4.6 Interpretation of Results

The outputs generated by AI models can be complex and difficult to interpret. Clinicians and researchers may struggle to translate these predictions into practical decisions in drug development or clinical practice. Improving explainability and user-friendly interfaces is necessary for wider adoption.

4.7 Ethical Considerations

The use of AI in drug development raises several ethical concerns, including patient privacy, data security, and data ownership. Sensitive health data must be handled carefully to protect patient rights. Regulatory agencies must establish clear guidelines for the safe and ethical use of AI. Ensuring patient safety, proper consent, and responsible use of animal models is also essential.

4.8 Complexity of Biological Systems

Biological systems are highly complex, involving multiple pathways, molecular interactions, and environmental factors. AI models may oversimplify these systems because available data may not fully capture their complexity. Drug distribution, absorption, and interactions within the body depend on many variables such as biological membranes, transport mechanisms, and pharmacokinetic parameters.

Although computational and AI models help analyze these processes, their predictions may still differ from real biological outcomes. Therefore, integrating system biology data and advanced modeling approaches is important to improve AI accuracy in drug delivery research.[9]

5. AI FOR PHARMACOKINETICS AND PHARMACODYNAMICS

5.1 AI -Based Prediction of Pharmacokinetic Parameters

AI algorithms such as Random Forest, Support Vector Machines, Decision Trees, Artificial Neural Networks, Convolutional Neural Networks (CNN), Recurrent Neural Networks (RNN), and Long Short-Term Memory (LSTM) are used to predict pharmacokinetic properties. These include ADME (Absorption, Distribution, Metabolism, and Excretion), bioavailability, drug clearance, and half-life. Quantitative Structure–Activity Relationship (QSAR) models are also used to predict drug behavior based on chemical structure.

5.2 AI-Based Physiologically Based Pharmacokinetic (PBPK) Modeling

Physiologically Based Pharmacokinetic (PBPK) models simulate drug movement within the human body by dividing it into compartments such as blood, liver, kidney, and other organs. AI improves PBPK modeling by selecting important parameters, enhancing prediction accuracy, and reducing the need for repeated animal or human studies.

5.3 Prediction of Drug Release and Absorption

AI techniques can predict drug release and absorption by analyzing factors such as solubility, permeability, and formulation design. These models help simulate how drugs are released from dosage forms such as tablets, transdermal patches, and inhalation systems, which assists in optimizing drug delivery.

5.4 Prediction of Metabolism and Excretion

AI models can predict how drugs are metabolized and eliminated from the body. They help identify metabolic pathways, detect enzymes involved in metabolism (such as Cytochrome P450), estimate drug clearance, and identify potential drug–drug interactions. This improves drug safety and supports personalized medicine.[11]

5 ADVANTAGES



Fig2: Overview of key applications of Artificial Intelligence in pharmaceutical sciences, including microfluidics, drug formulation, drug–excipient compatibility, drug solubility and availability, nanomedicine, and personalized medicine.

6. FASTER DRUG DEVELOPMENT

AI can analyze large biological and chemical datasets quickly, helping researchers identify potential drug candidates in a shorter time. This significantly accelerates the drug discovery and formulation development process.

6.1 Improved Accuracy and Prediction

Machine learning algorithms can accurately predict drug properties such as solubility, stability, bioavailability, and toxicity. This improves the reliability of pharmaceutical research and formulation design.

6.2 Cost Reduction in Research and Development

AI reduces the need for extensive laboratory experiments and clinical trials by predicting outcomes through computational models. This helps pharmaceutical companies lower research and development costs.

6.3 Optimization of Drug Formulations

AI helps in optimizing dosage forms such as tablets, capsules, nanoparticles, liposomes, and transdermal systems by selecting suitable excipients and formulation parameters.

6.4 Personalized Medicine

AI can analyze patient-specific data such as genetics, medical history, and lifestyle to design personalized drug therapies and drug delivery systems tailored to individual patients.[12]

6.5 Improved Drug Delivery Systems

AI supports the design of advanced drug delivery systems including targeted drug delivery, controlled release formulations, and smart drug carriers, improving therapeutic effectiveness and reducing side effects.

7. DISADVANTAGES



Figure 3. Artificial Intelligence–driven cycle in pharmaceutical research and development, highlighting the iterative stages of design, formulation, testing, and analysis for optimized drug development.

7.1 High Implementation Cost

The adoption of AI technologies requires advanced computing infrastructure, specialized software, and skilled professionals. These requirements make the implementation of AI systems expensive for many pharmaceutical organizations.[13]

7.2 Lack of High-Quality Data

AI models depend on large and reliable datasets for accurate predictions. In pharmaceutical research, limited or poor-quality data can reduce the effectiveness and reliability of AI-based models.

7.3 Limited Transparency (Black Box Problem)

Many AI models, especially deep learning systems, operate as "black boxes," meaning their decision-making processes are difficult to interpret. This lack of transparency can create challenges for researchers and regulatory authorities.

7.4 Regulatory and Ethical Issues

The use of AI in pharmaceutical research raises regulatory and ethical concerns. Strict validation and regulatory approval are required before AI-based technologies can be widely applied in drug development.

7.5 Dependence on Technical Expertise

Effective implementation of AI requires professionals with knowledge in data science, machine learning, and pharmaceutical sciences. The shortage of such multidisciplinary expertise can limit the adoption of AI.

7.6 Risk of Prediction Errors

AI predictions may be inaccurate if models are trained on incomplete or biased data. Incorrect predictions could affect drug safety, efficacy, and formulation decisions.

7.7 Data Privacy and Security Concerns

AI systems often process sensitive patient and clinical information. Protecting this data and maintaining privacy and security is a significant challenge in AI-based pharmaceutical applications.[14]

8. APPLICATIONS OF AI



Figure 4. AI-driven ecosystem in healthcare and pharmaceutical research showing interactions between patients, physicians, radiologists, researchers, CRO laboratories, and drug developers through data integration, predictive analysis, diagnostics, and clinical decision support.

8.1 Drug Discovery and Development

AI helps identify new drug candidates by analyzing large chemical and biological datasets, significantly accelerating the drug discovery process.

8.2 Drug Formulation Design

AI assists in selecting suitable excipients and optimizing formulation parameters for dosage forms such as tablets, capsules, and nanoparticles.

8.3 Prediction of Drug–Target Interactions

Machine learning models can predict interactions between drugs and biological targets, helping in the identification of potential therapeutic effects.

8.4 Optimization of Drug Delivery Systems

AI helps design advanced drug delivery systems such as controlled release, sustained release, and targeted drug delivery formulations.[15]

8.5 Prediction of Pharmacokinetic and Pharmacodynamic Properties

AI models predict ADME properties, bioavailability, half-life, and drug clearance, improving the understanding of drug behavior in the body.

8.6 Toxicity Prediction

AI tools can predict potential toxicity and side effects of drug candidates before clinical trials, improving drug safety.

8.7 Personalized Medicine

AI analyzes patient-specific data such as genetics and medical history to develop personalized treatment strategies.

8.8 Clinical Trial Optimization

AI helps design efficient clinical trials by selecting suitable patient groups and predicting trial outcomes.[16]

8.9 Drug Repurposing

AI can identify new therapeutic uses for existing drugs by analyzing biological and clinical data.

8.10 Quality Control in Pharmaceutical Manufacturing

AI systems monitor manufacturing processes to ensure consistent drug quality and detect defects early.

8.11 Prediction of Drug Stability

AI models can predict how drugs behave under different environmental conditions such as temperature, humidity, and light.

8.12 Nanotechnology-Based Drug Delivery

AI assists in designing nanoparticles and nanocarriers for targeted drug delivery and improved therapeutic efficiency.[17]

8.13 Intelligent Drug Release Systems

AI helps design smart drug delivery systems that release drugs at controlled rates based on physiological conditions.

8.14 Pharmaceutical Supply Chain Management

AI improves inventory management, demand forecasting, and distribution efficiency in the pharmaceutical supply chain.

8.15 Data Analysis in Pharmaceutical Research

AI can process and analyze large pharmaceutical datasets quickly, enabling faster research insights and innovation.[18]

9. CONCLUSION

Artificial Intelligence (AI) is playing an important role in transforming pharmaceutical technology and drug delivery system design. By using techniques such as machine learning and deep learning, AI helps researchers analyze large datasets, identify potential drug candidates, and optimize drug formulations more efficiently. It also improves pharmacokinetic predictions, drug safety evaluation, and the development of advanced drug delivery systems such

as targeted and controlled release formulations.[19]

Although challenges such as data limitations, model transparency, and regulatory concerns still exist, continuous advancements in AI technologies are expected to overcome these issues. Overall, AI has great potential to accelerate drug development, enhance pharmaceutical research, and support the future of personalized medicine.[20]

AKNOWLEDGMENT

The authors would like to express their sincere gratitude to the faculty members and mentors of the Department of Pharmaceutical Sciences for their valuable guidance, encouragement, and support during the preparation of this review article. Their continuous motivation and academic insights greatly contributed to the completion of this work.

The authors also acknowledge the availability of scientific literature, journals, and online databases that provided essential information for this review. Finally, we extend our appreciation to all researchers and scientists whose studies in the field of Artificial Intelligence and pharmaceutical technology have made this work possible.

REFERENCES:

1. Mak, K. K., & Pichika, M. R. (2019). Artificial intelligence in drug development: Present status and future prospects. Drug Discovery Today, 24(3), 773–780.
2. Vamathevan, J., Clark, D., Czodrowski, P., Dunham, I., Ferran, E., Lee, G., Li, B., Madabhushi, A., Shah, P., Spitzer, M., & Zhao, S. (2019). Applications of machine learning in drug discovery and development. Nature Reviews Drug Discovery, 18(6), 463–477.
3. Paul, D., Sanap, G., Shenoy, S., Kalyane, D., Kalia, K., & Tekade, R. K. (2021). Artificial intelligence in drug discovery and development. Drug Discovery Today, 26(1), 80–93.
4. Schneider, G. (2018). Automating drug discovery. Nature Reviews Drug Discovery, 17(2), 97–113.
5. Mayr, A., Klambauer, G., Unterthiner, T., & Hochreiter, S. (2016). Deep learning in drug discovery. Molecular Informatics, 35(11–12), 513–524
6. Chen, H., Engkvist, O., Wang, Y., Olivecrona, M., & Blaschke, T. (2018). The rise of deep learning in drug discovery. Drug Discovery Today, 23(6), 1241–1250.
7. Kalyane, D., Sanap, G., Paul, D., Shenoy, S., Kalia, K., & Tekade, R. K. (2020). Artificial intelligence in the pharmaceutical sector: Current scenario and future prospects. Pharmacological Research, 156, 104731.
8. Ching, T., Himmelstein, D. S., Beaulieu-Jones, B., et al. (2018). Opportunities and obstacles

for deep learning in biology and medicine. Journal of the Royal Society Interface, 15(141), 20170387.

9. Ekins, S. (2016). The next era: Deep learning in pharmaceutical research. Pharmaceutical Research, 33(11), 2594–2603.
10. 10.Kirchmair, J., Göller, A. H., Lang, D., et al. (2015). Predicting drug metabolism: Experiment and/or computation? Nature Reviews Drug Discovery, 14(6), 387–404
11. Zhavoronkov, A., Ivanenkov, Y., Aliper, A., et al. (2019). Deep learning enables rapid identification of potent DDR1 kinase inhibitors. Nature Biotechnology, 37, 1038–1040.
12. Topol, E. J. (2019). High-performance medicine: The convergence of human and artificial intelligence. Nature Medicine, 25, 44–56.
13. Yu, K. H., Beam, A. L., & Kohane, I. S. (2018). Artificial intelligence in healthcare. Nature Biomedical Engineering, 2, 719–731.
14. Harrer, S., Shah, P., Antony, B., & Hu, J. (2019). Artificial intelligence for clinical trial design. Trends in Pharmacological Sciences, 40(8), 577–591.
15. Chan, H. S., Shan, H., Dahoun, T., Vogel, H., & Yuan, S. (2019). Advancing drug discovery via artificial intelligence. Trends in Pharmacological Sciences, 40(8), 592–604.
16. Rifaioglu, A. S., Atas, H., Martin, M. J., Cetin-Atalay, R., Atalay, V., & Dogan, T. (2019). Recent applications of deep learning in bioinformatics and drug discovery. Frontiers in Bioengineering and Biotechnology, 7, 187.
17. Kesharwani, P., Gupta, U., & Jain, N. K. (2012). Dendrimers as nanocarriers for drug delivery. Progress in Polymer Science, 39(2), 268–307.
18. Stokes, J. M., Yang, K., Swanson, K., et al. (2020). A deep learning approach to antibiotic discovery. Cell, 180(4), 688–702.
19. Jumper, J., Evans, R., Pritzel, A., et al. (2021). Highly accurate protein structure prediction with AlphaFold. Nature, 596, 583–589.
20. Schneider, P., Walters, W. P., & Plowright, A. T. (2020). Rethinking drug design in the artificial intelligence era. Nature Reviews Drug Discovery, 19, 353–364.